



Antibacterial Resistance and Infection Control in ICU

Guest Editors:

Dr. Daniela C. Pasero

Anaesthesiology and Intensive
Care Medicine, Department of
Medicine, Surgery and Pharmacy,
University of Sassari, 07100
Sassari, Italy

Dr. Francesco Forfori

Department of Surgical, Medical
and Molecular Pathology and
Critical Care Medicine, University
of Pisa, Pisa, Italy

Deadline for manuscript
submissions:

20 October 2024

Message from the Guest Editors

Dear Colleagues,

The increasing pressure of antimicrobial resistance (AMR) in healthcare-associated infections (HAIs), especially in critically ill patients, is one of the main challenging emergency issues to solve worldwide.

The aim of this Special Issue is to examine all the possible strategies that might contribute to reducing antimicrobial resistance and allow the control of HAIs. You can give your contribution with an original article, a systematic review or meta-analysis, and review articles.

The main topics are as follows:

1. Epidemiology of healthcare-associated infections (HAIs).
2. Infection control in the ICU.
3. How can microbiology have an impact on antimicrobial resistance control?
4. IVAC/VAP in the ICU—from prevention to treatment.
5. Could we reach “zero” CR-BSI?
6. SSI: where we are—do the bundles work?
7. Management of intra-abdominal infection.
8. Empirical treatment or semi-targeted therapy—what is the dilemma?
9. Role of PK/PD in improving AMR control. How to optimize antibiotic therapy in critically ill patients.
10. De-escalation—is it feasible in critically ill patients?
11. When to stop antimicrobial therapy.
12. Biomarkers and AMR.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)